Understanding Hospital-Acquired Infections (HAIs) in Mexico
In recent years, an invisible enemy has crept into the top four causes of death in Mexico: Hospital-Acquired Infections (HAIs). This term, familiar to healthcare professionals, refers to any infectious complication arising from medical interventions. It’s not an abstract problem; it’s a reality affecting one in five hospitalized patients, with 10% of those tragically losing their lives.
Extrapolating these figures to the annual hospitalizations in Mexico paints a catastrophic picture. However, these numbers are based on the available data, and there’s an underreporting issue that hides the true extent of the problem.
Experts’ Perspectives at the 2025 Forum on Hospital-Acquired Infections
At the fifth Forum “The Challenge of Hospital-Acquired Infections” held in September 2025, authoritative voices in this field highlighted the situation. Among them was Dr. Samuel Ponce de León, a professor at the UNAM Medical Faculty and coordinator of the Program for Research on Epidemiological and Emerging Risks (PUIREE). He has been a persistent advocate for this issue. Dr. Ponce de León explained that HAIs result from common medical procedures, such as inserting breathing tubes, ventilators, Foley catheters, or central lines. Given that over 70% of hospitalized patients require some form of catheter, be it short or more complex, hospital admission inherently carries a risk of acquiring a nosocomial infection.
The gravity of these infections lies not only in prolonging hospital stays but also in causing immense emotional distress: unnecessary suffering, loneliness in a hostile environment, and, in the worst-case scenario, loss of life.
Economic and Social Impact
Moreover, each hospital-acquired infection imposes additional costs on families and medical institutions. For public hospitals, these extra expenses strain already underfunded systems with known shortcomings. This creates a vicious cycle where resource scarcity increases the risk of more infections and other adverse events, eroding trust in the healthcare sector.
Dr. Ponce de León emphasized the need for hospitals to implement prospective surveillance systems and targeted interventions for each procedure, stressing collaboration with health authorities. Mexico has crucial tools like the Norma Oficial Mexicana (NOM 035) for controlling HAIs, but it has been pending an update for over a year and is eagerly awaited.
Antibiotic Overuse Fuels Antimicrobial Resistance
Without concrete actions to prevent HAIs, the outlook is bleak: hospitals with ineffective antibiotics, untreatable infections, and unsustainable costs threatening the healthcare system’s viability. This scenario intertwines with antibiotic misuse in Mexico, accelerating antimicrobial resistance (AMR). In 2025, UNAM experts reported at least 50 million unnecessary prescriptions annually, contributing to AMR becoming a leading global mortality cause by 2050, potentially causing 10 million deaths yearly.
Self-medication exacerbates side effects like diarrhea and allergies, while the WHO has noted a 40% increase in pathogen-antibiotic resistance between 2018 and 2023. Hospital studies reveal overprescription of broad-spectrum antibiotics, directly linked to bacterial resistance and worsened by stress and obesity, which exacerbate gastrointestinal issues.
Key Questions and Answers
- What are Hospital-Acquired Infections (HAIs)? HAIs are infections patients contract during their hospital stay due to medical interventions.
- How prevalent are HAIs in Mexico? One in five hospitalized patients experiences a HAI, with 10% of those succumbing to the infection.
- What are the consequences of HAIs? HAIs prolong hospital stays, cause emotional distress, and impose additional economic burdens on patients and healthcare institutions.
- How does antibiotic misuse contribute to the problem? Antibiotic overuse fuels antimicrobial resistance, making infections harder to treat and threatening healthcare systems’ viability.
- What solutions are being proposed? Experts advocate for prospective surveillance systems, targeted interventions, rational antibiotic use, and investments in prevention, education, and research.
